Protagenic Therapeutics Inc. entered into a Warrant Exchange Agreement on May 20, 2025, with an unaffiliated third-party investor. The agreement involves the cancellation and retirement of 459,420 warrants in exchange for 367,544 shares of the company's common stock. The price per share is not specified in the document.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.